Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- an article about a recent Federal Circuit decision addressing estoppel in inter partes review patent proceedings;
- an article discussing another recent decision in which an “Endo International Plc subsidiary failed to convince the Federal Circuit that a generic version of its bestselling blood-pressure drug infringed its patents”;
- a third article summarizing another recent decision invoking “the rule prohibiting recapture of subject matter surrendered during prosecution” following an amendment “to overcome a § 101 patent eligibility rejection.”